Table1.

Summary of clinicopathological features of the studied prostate cancer cohort at the time of diagnosis, patient demographics of the studied prostate cancer cohort, and cases with recurrence and no recurrence within the studied prostate cancer cohort

Clinicopathological cohort, n (%)
	Recurrence	Nonrecurrence	Total
No. of patients	22 (31.4)	48 (68.6)	70
Gleason score
6	1 (11.1)	8 (88.9)	9 (12.9)
7 (3 + 4)	3 (17.7)	14 (82.3)	17 (24.3)
7 (4 + 3)	3 (16.7)	15 (83.3)	18 (25.7)
8	8 (47.1)	9 (52.9)	17 (24.3)
9	7 (77.8)	2 (22.2)	9 (12.9)
Primary tumor stage
pT2	2 (6.9)	27 (93.1)	29 (41.4)
pT3a	15 (48.4)	16 (51.6)	31 (44.3)
pT3b	5 (62.5)	3 (37.5)	8 (11.4)
Unknown	0 (0)	2 (100)	2 (2.9)
Lymph node
Positive	0 (0)	1 (100)	1 (1.4)
Negative	22 (31.9)	47 (68.1)	69 (98.6)
Surgical margin
Positive	20 (51.3)	19 (48.7)	39 (55.7)
Negative	2 (6.4)	29 (93.5)	31 (44.3)
Presurgical PSA, ng/mL
0–10	12 (25.0)	36 (75.0)	48 (68.6)
10–20	6 (37.5)	10 (62.5)	16 (22.9)
20–30	2 (66.7)	1 (33.3)	3 (4.3)
30–40	2 (66.7)	1 (33.3)	3 (4.3)
Patient demographics, mean ± SD
Variable	Recurrence		Nonrecurrence
Age, yr	59.04 ± 6.57		58.82 ± 5.80
Gland weight, g	51.94 ± 14.90		56.19 ± 21.38
PSA, ng/ml	8.29 ± 5.29		13.17 ± 10.15
PSAD, ng/ml/g	0.17 ± 0.11		0.25 ± 0.20
Time to event, yr	5.06 ± 4.50		3.82 ± 2.36
Outcomes for recurrence and no recurrence, n
Recurrence			22
Died from prostate cancer			2
Died from another cause with recurrence			1
Distant metastasis			1
Increase in PSA (>0.2 ng/ml)			14
Local recurrence			1
Local recurrence and distant metastasis			3
No recurrence			48
Died from noncancer cause			1
No recurrence			47

PSA = prostate-specific antigen; PSAD = prostate-specific antigen density; SD = standard deviation.